Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful impr
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
07:00am, Wednesday, 09'th Apr 2025
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy
08:35am, Tuesday, 25'th Mar 2025
Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mire
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript
12:25pm, Thursday, 06'th Mar 2025
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of S
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics
07:30pm, Wednesday, 05'th Mar 2025
The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wa
Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates
06:10pm, Wednesday, 05'th Mar 2025
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.12 per share a year ago.
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:01pm, Wednesday, 05'th Mar 2025
WARREN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful im
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
07:00am, Wednesday, 12'th Feb 2025
WARREN, N.J., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp
Aquestive Therapeutics: Five Foci For 2025
12:13am, Monday, 06'th Jan 2025
Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by EpiPen, with peak sales estimated at $300–400M. AQST-108, a topical epinephr
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics +
08:00am, Saturday, 09'th Nov 2024
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Xometry's AI-driven procurement software in
Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call Transcript
03:57pm, Tuesday, 05'th Nov 2024
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q3 2024 Earnings Call Transcript November 5, 2024 8:00 AM ET Company Participants Bennett Watson - IR, ICR Westwicke IR Dan Barber - CEO Ernie Toth - CFO Sh
Aquestive: Rare Opportunity With Dual Platform Strategy
02:09pm, Tuesday, 05'th Nov 2024
Aquestive Therapeutics specializes in innovative film-based medicines and epinephrine products & delivery. The company's PharmFilm and Adrenaverse platforms offer unique competitive advantages, making
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
08:00pm, Monday, 04'th Nov 2024
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compar
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
06:50pm, Monday, 04'th Nov 2024
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.03 per share a year ago.
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
04:36pm, Monday, 04'th Nov 2024
WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
